{"groups":[{"description":"Single dose of 1-3x10\\^7 huCARTmeso cells/m\\^2\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"FG000","title":"Cohort 1"},{"description":"Cyclophosphamide 1 gram/m\\^2 administered 2-4 days prior to a single dose of 1-3x10\\^7 huCARTmeso cells/m\\^2\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"FG001","title":"Cohort 2"},{"description":"PERMANENTLY CLOSED\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"FG002","title":"Cohort 3"},{"description":"PERMANENTLY CLOSED\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"FG003","title":"Cohort 4"},{"description":"Single dose of 1-3x10\\^7 huCART-meso cells/m\\^2 day 0 by intrapleural infusion (IP) through an indwelling pleural catheter without any conditioning chemotherapeutic regimen.\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"FG004","title":"Cohort 5"},{"description":"Cyclophosphamide 1 gram/m\\^2 administered 2-4 days prior to dose of 1-3x10\\^7 huCART-meso cells/m\\^2 via IV infusion on Day 0. This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given approximately 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells.\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"FG005","title":"Cohort 6"},{"description":"Cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day given over 3 days by IV infusion followed by a single dose of 1-3x10\\^7 huCART-meso cells/m\\^2 via intraperitoneal (i.p.) administration. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells.\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"FG006","title":"Cohort 7"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"8"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Protocol specifies that a consented participant is an enrolled participant. 65 participants were consented. Of these, 34 were ineligible and 31 were eligible. Of the 31 eligible, one participant was never assigned to a cohort. This participant was withdrawn prior to assignment due to disease progression.\n\nThe remaining 30 participants are detailed below."}